АФФЕКТИВНЫЕ РАССТРОЙСТВА В ДЕБЮТЕ БОЛЕЗНИ ПАРКИНСОНА. КЛИНИЧЕСКИЙ СЛУЧАЙ
М. А. Самушия
ФГБУ ДПО «Центральная государственная медицинская академия» УД Президента РФ
А. А. Рагимова
ФГБУ ДПО «Центральная государственная медицинская академия» УД Президента РФ
И. Г. Смоленцева
ФГБУ ДПО «Центральная государственная медицинская академия» УД Президента РФ
М. Ю. Максименко
ФГБУ ДПО «Центральная государственная медицинская академия» УД Президента РФ

Ключевые слова

болезнь Паркинсона
депрессия
неврология
психиатрия

Как цитировать

[1]
.

Аннотация

Аффективные расстройства являются распространённым немоторным проявлением болезни Паркинсона (БП), определяющим качество жизни, комплаентность к лечению и прогноз заболевания. По данным литературы распространённость биполярного аффективного расстройства до манифеста БП составляется 6%.  В статье клинический случай пациентки с биполярным течением аффективного расстройства, предшествующем началу моторных симптомов БП.

Литература

1. Schapira A, Chaudhuri K, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017; 18(7): 435-450. doi: 10.1038/nrn.2017.62
2. Иллариошкин С.Н. Современные подходы к молекулярной и персонализированной терапии болезни Паркинсона. Вестник Российской военно-медицинской академии. 2018; S3: 47-49.
3. Руководство по диагностике и лечению болезни Паркинсона. Под ред. Иллариошкина С.Н., Левина О.С. М.: ИПК Парето-Принт; 2017. с. 336.
4. Khegai О, Selyanina N. Comparative characteristics of non-motor manifestations of Parkinson disease in men and women. Med Almanac. 2018; 5: 120-122. doi: 10.21145/2499-9954-2018-5-120-122
5. Titova N, Padmakumar C, Kewis S, Chaudhuri KR. Parkinson’s: a Syndrome Rather than a Disease? J Neural Transm (Vienna). 2016; 124(8): 907–914. doi:10.1007/s00702-016-1667-6.
6. Patel RS, Makani R, Mansuri Z, Patel U, Desai R, Chopra A. Impact of Depression on Hospitalization and Related Outcomes for Parkinsons Disease Patients: A Nationwide Inpatient Sample-Based Retrospective Study. Cureus. 2017; 9: e1948. doi:10.7759/cureus.1648
7. Singian KRP, Price M, Bungay V, Wong ST. Using Canadian Primary Care Sentinel Surveillance Network data to examine depression in patients with a diagnosis of Parkinson disease: a retrospective cohort study. CMAJ Open. 2016; 4(3): 417-423. doi:10.9778/cmajo.20160052.
8. Wee N, Kandiah N, Acharyya S, Chander R, Ng A, Au WL, Tan LC. Depression and anxiety are co-morbid but dissociable in mild Parkinsons disease: A prospective longitudinal study of patterns and predictors. Parkinsonism Relat Disord. 2016; 23: 50-56. doi:10.1016/j.parkreldis.2015.12.001.
9. Spottke AE, Reuter M, Machat O, Bornschein B, von Campenhausen S, Berger K et al. Cost of Illness and its Predictors for Parkinsons Disease in Germany. PharmacoEconomics. 2005; 23(8): 817-836. doi:10.2165/00019053-200523080-00007.
10. Palmeri R, Lo Buono V, Corallo F, Foti M, Di Lorenzo G, Bramanti P et al. Nonmotor Symptoms in Parkinson Disease: A Descriptive Review on Social Cognition Ability. J Geriatr Psychiatry Neurol. 2017; 30(2): 109–121. doi:10.1177/0891988716687872.
11. Li K, Reichmann H, Ziemmsen T, Ziemssen T. Recognition and Treatment of Autonomic Disturbances in Parkinson’s Disease. Expert Rev Neurother. 2015; 15(10): 1189–1203. doi:10.1586/14737175.2015.1095093.
12. Berg D, Postuma R, Adler C, Bloem BR, Chan P, Dubois B et al. MDS Research Criteria for Prodromal Parkinsons Disease. Mov Disord. 2015; 30(12): 1600–1611. doi:10.1002/mds.26431.
13. Titova N, Chaudhuri R. Personalized Medicine in Parkinsons Disease: Time to Be Precise. Mov Disord. 2017; 32(8): 1147–1154. doi:10.1002/mds.27027.
14. Katunina E, Titova N. The Epidemiology of Nonmotor Symptoms in Parkinsons Disease (Cohort and Other Studies). Int Rev Neurobiol. 2017; 133: 91–110. doi:10.1016/bs.irn.2017.05.012.
15. Todorova A, Jenner P, Chaudhuri R. Non-Motor Parkinsons: Integral to Motor Parkinsons, Yet Often Neglected. Pract Neurol. 2014; 14(5): 310–322. doi:10.1136/practneurol-2013-000741.
16. Reijnders J, Ehrt U, Weber W, Aarsland D, Leentjens AF. A Systematic Review of Prevalence Studies of Depression in Parkinsons Disease. Mov Disord. 2017; 23(2): 183–189. doi:10.1002/mds.21803.
17. Нодель М. Р. Влияние нервно-психических нарушений на качество жизни пациентов с болезнью Паркинсона. Неврологический журнал. 2015; 20(1): 20-27.
18. Hoehn M, Yahr M. Parkinsonism: Onset, Progression, and Mortality. Neurology. 1967; 17(5): 427–427. doi:10.1212/wnl.17.5.427.
19. Pfeiffer R. Non-Motor Symptoms in Parkinsons Disease. Parkinsonism Relat Disord. 2016; 22: 119-122. doi:10.1016/j.parkreldis.2015.09.004.
20. Kehagia A, Barker R, Robbins T. Neuropsychological and Clinical Heterogeneity of Cognitive Impairment and Dementia in Patients with Parkinsons Disease. Neurol. 2010; 9(12): 1200–1213. doi:10.1016/s1474-4422(10)70212-x.
21. Hughes T, Ross H, Mindham R, Spokes EG. Mortality in Parkinson’s Disease and Its Association with Dementia and Depression. Acta Neurol Scand. 2004; 110(2): 118–123. doi:10.1111/j.1600-0404.2004.00292.x.
22. De Lau L, Verbaan D, Marinus J, van Hilten JJ. Survival in Parkinsons Disease. Relation with Motor and Non-Motor Features. Parkinsonism Relat Disord. 2014; 20(6): 613–616. doi:10.1016/j.parkreldis.2014.02.030.
23. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson’s disease: Loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005; 128(6): 1314-1322. doi:10.1093/brain/awh445
24. Wen M-C, Chan LL, Tan LCS, Tan EK. Depression, anxiety, and apathy in Parkinsons disease: insights from neuroimaging studies. Eur J Neurol. 2016; 23(6): 1001-1019. doi:10.1111/ene.13002.
25. Chen J, Marsh L. Anxiety in Parkinson’s disease: Identification and management. Therapeutic Advances in Neurological Disorders. 2013; 7(1): 52-59. doi:10.1177/1756285613495723
26. Ahn S, Lee J, Chu SH, Sohn YH. Uncertainty and depression in people with Parkinson’s disease: A cross-sectional study. Nurs Health Sci. 2017; 19(2): 220-227. doi:10.1111/nhs.12332.
27. Rodríguez-Violante M, de Sarachaga A, Cervantes-Arriaga A, Davila-Avila M, Carrion-Bautista E, Estrada-Bellmann I et al. Premotor Symptoms and the Risk of Parkinson’s Disease: A Case-Control Study in Mexican Population. Clin Neurol Neurosurg. 2017; 160: 46–49., doi:10.1016/j.clineuro.2017.06.010.
28. Landau S, Harris V, Burn DJ, Hindle J, Hurt C, Samuel M et al. Anxiety and anxious-depression in Parkinsons disease over a 4-year period: a latent transition analysis. Psychologic Med. 2015; 46(03): 657-667. doi:10.1017/s0033291715002196.
29. Moonen A, Wijers A, Leentjens A, Christine C, Factor S, Juncos J et al. Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinsons disease. Parkinsonism Relat Disord. 2014; 20(6): 644-646. doi:10.1016/j.parkreldis.2014.02.025.
30. Dissanayaka NNNW, White E, O'Sullivan JD, Marsh R, Pachana NA, Byrne GJ. The clinical spectrum of anxiety in Parkinson's disease. Mov Disord. 2014; 29(8): 967-975. doi: 10.1002/mds.25937.
31. Dissanayaka NNW, O'Sullivan JD, Pachana NA, Marsh R, Silburn P, White EX et al. Disease-specific anxiety symptomatology in Parkinson's disease. Inter Psychogeriatr. 2016; 28(7): 1153-63. doi: 10.1017/S1041610215002410.
32. Poletti M, Frosini D, Pagni C, Lucetti C, Del Dotto P, Tognoni G et al. The Association between Motor Subtypes and Alexithymia in De Novo Parkinson’s Disease. J Neurol. 2011; 258(6): 1042–1045., doi:10.1007/s00415-010-5878-8.
33. Costa A, Peppe A, Carlesimo GA, Pasqualetti P, Caltagirone C. Alexithymia in Parkinsons disease is related to severity of depressive symptoms. Eur J Neurol. 2006; 13(8): 836-841. doi:10.1111/j.1468-1331.2006.01216.x.
34. Bykov K, Yoshida K, Weisskopf M, Gagne J. Confounding of the association between statins and Parkinson disease: Systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2016; 26(3): 294-300. doi:10.1002/pds.4079
35. Lhommee E, Klinger H, Thobois S, Schmitt E, Ardouinn C, Bichon A et al. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Brain. 2012; 135(5): 1463–1477. https://doi.org/10.1093/brain/aws078
36. Aarsland D, Bronnick K, Alves G, Tysnes O, Pedersen K, Ehrt U et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry. 2009: 80(8): 928–930. https://doi.org/10.1136/jnnp.2008.166959
37. Dujardin K, Sockeel P, Devos D, Delliaux M, Krystkowiak P, Destee A et al. Characteristics of apathy in Parkinson's disease. Mov Disord. 2007; 22(6): 778–784. https://doi.org/10.1002/mds.21316
38. Lemke MR. Depressive symptoms in Parkinson’s disease. Eur J Neurol. 2008; 15(s1): 21-25. doi:10.1111/j.1468-1331.2008.02058.x.
39. Radakovic R, Davenport R, Starr JM, Abrahams S. Apathy dimensions in Parkinsons disease. Inter J Geriatr Psychiatry. 2017; 33(1): 151-158. doi:10.1002/gps.4697.
40. Maillet A, Krack P, Lhommée E, Metereau E, Klinger H, Favre E. et al. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease. Brain. 2016; 139(9): 2486-2502. doi:10.1093/brain/aww162.
41. Reichmann H. Premotor Diagnosis of Parkinson’s Disease. Neurosci Bull. 2017; 33(5): 526–534. doi:10.1007/s12264-017-0159-5.
42. Engmann B. Bipolar Affective Disorder and Parkinsons Disease. Case Rep Med. 2011; 2011: 154-165. doi:10.1155/2011/154165.
43. Lin H-L, Lin H-C, Chen Y-H. Psychiatric diseases predated the occurrence of Parkinson disease: a retrospective cohort study. Ann Epidemiol. 2014; 24(3): 206-213. doi:10.1016/j.annepidem.2013.12.010
44. Novaretti TM, Novaretti N, Tumas V. Bipolar disorder, a precursor of Parkinsons disease? Dement Neuropsychol. 2016; 10(4): 361-364. doi:10.1590/s1980-5764-2016dn1004018.
45. Weintraub D, David AS, Evans AH, Grant JE, Stacy M. Clinical spectrum of impulse control disorders in Parkinsons disease. Mov Disord. 2014; 30(2): 121-127. doi:10.1002/mds.26016.
46. Steinlechner S, Hagenah J, Rumpf HJ, Meyer C, John U, Baumer T. et al. Associations of specific psychiatric disorders with isolated focal dystonia, and monogenic and idiopathic Parkinson's disease. J Neurol. 2017; 264(6): 1076-1084. doi: 10.1007/s00415-017-8488-x.
47. Friedman JH. Misperceptions and Parkinson's disease. J Neurol Sci. 2017; 15(374): 42-46. doi: 10.1016/j.jns.2016.12.059.
48. Sozhinova E.V. Personality of patient with Parkinson's disease. Lechenie zabolevanij nervnoj sistemy. 2010; 1(3): 29-33. In Russian.
49. Smulevich A. B. Schizophrenia spectrum disorders in general medical practice. Zhurnal nevrologii i psihiatrii im. S. S. Korsakova. 2015; 116(1): 4-9. In Russian.
50. Girolamo G, Bani M, Dagani J, Ferrari C, Pastore A, Signorini G. Age of Onset of Bipolar Disorders: A Systematic Review and Meta-Analysis. Eur Psychiatry. 2016; 33: s56. doi:10.1016/j.eurpsy.2016.01.935.
51. Нодель М.Р., Яхно Н.Н. Апатия при болезни Паркинсона. Неврологический журнал. 2014; 1: 9-15.
52. Яковлева О.В., Полуэктов М.Г., Ляшенко Е.А., Левин О.С. Сон и когнитивные нарушения при нейродегенеративных заболеваниях. Журнал неврологии и психиатрии им. C.C. Корсакова. 2019. 119; 4-2: 89-98.
53. Амосова Н.А., Смоленцева И.Г., Гусейнова П.М., Маслюк О.А., Гаврилов Э.Л. Нарушения сна на ранней стадии болезни паркинсона у пациентов, не принимающих противопаркинсонические препараты. Журнал неврологии и психиатрии им. C.C. Корсакова. 2016. 116; 6-2: 77-81.
54. Wunderink L, Nieboer R, Wiersma D, Sytema S, Nienhuis F. Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy. JAMA Psychiatry. 2013; 70(9), 913. doi:10.1001/jamapsychiatry.2013.19
55. Poewe W. The premorbid personality of patients with Parkinson’s disease. Adv Neurol. 1990; 53: 339-42.